XOMA Royalty (XOMA) Total Current Liabilities (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Total Current Liabilities came in at $33.1 million in Q1 2026, up 61.87% year-on-year from $20.4 million in Q1 2025, and down 5.01% quarter-over-quarter from $34.8 million in Q4 2025.
XOMA Royalty (XOMA) Total Current Liabilities (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Total Current Liabilities across 17 years of filings, most recently posting $33.1 million for Q1 2026.
- Total Current Liabilities for Q1 2026 came in at $33.1 million, up 61.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $33.1 million (up 61.87% YoY), and the FY2025 annual result was $34.8 million, up 42.86% from the prior year.
- Total Current Liabilities came in at $33.1 million for Q1 2026 at XOMA Royalty, down from $34.8 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $34.8 million in Q4 2025 to a low of $5.4 million in Q3 2022.
- The 5-year median for Total Current Liabilities is $18.6 million (2024), against an average of $17.3 million.
- Across the five-year window, Total Current Liabilities slumped 47.42% in 2022 and jumped 185.99% in 2023, its largest moves.
- XOMA Royalty's Total Current Liabilities stood at $6.8 million in 2022, then surged by 185.99% to $19.5 million in 2023, then grew by 25.0% to $24.4 million in 2024, then surged by 42.86% to $34.8 million in 2025, then decreased by 5.01% to $33.1 million in 2026.
- The last three Total Current Liabilities figures came in at $33.1 million (Q1 2026), $34.8 million (Q4 2025), and $28.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | 1.70 Mn |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 636.40 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 13.42 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 3.88 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 72.86 Mn |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | 33.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33.08 Mn |
| Dec 31, 2025 | 34.82 Mn |
| Sep 30, 2025 | 28.31 Mn |
| Jun 30, 2025 | 21.50 Mn |
| Mar 31, 2025 | 20.43 Mn |
| Dec 31, 2024 | 24.37 Mn |
| Sep 30, 2024 | 21.13 Mn |
| Jun 30, 2024 | 18.62 Mn |
| Mar 31, 2024 | 15.54 Mn |
| Dec 31, 2023 | 19.50 Mn |
| Sep 30, 2023 | 10.33 Mn |
| Jun 30, 2023 | 7.09 Mn |
| Mar 31, 2023 | 10.09 Mn |
| Dec 31, 2022 | 6.82 Mn |
| Sep 30, 2022 | 5.43 Mn |
| Jun 30, 2022 | 8.42 Mn |
| Mar 31, 2022 | 7.89 Mn |
| Dec 31, 2021 | 12.97 Mn |
| Sep 30, 2021 | 6.51 Mn |
| Jun 30, 2021 | 6.29 Mn |